Preston Klassen bought stock once, on Jun 3, 2025
Pres, Head of R, D at Regulus Therapeutics Inc., and 2 other companies
SEC CIK 0001493056 · Filings on SEC.gov ↗
Preston Klassen's record
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Companies
Every filing
3 filings since Jan 2019, newest first
About Preston Klassen
Preston S. Klassen, M.D., is a Person and a biotechnology executive currently serving as President and Head of Research & Development at Regulus Therapeutics, a role he has held since June 2023; he also joined the company’s Board of Directors in 2023.( Regulus describes itself as a biopharmaceutical company focused on discovering and developing medicines targeting microRNAs.(
Dr. Klassen is a trained nephrologist with more than 20 years of experience across pharmaceutical leadership, medical affairs, and R&D.( Before Regulus, he was President and CEO of Metacrine, EVP and Head of R&D at Arena Pharmaceuticals, and held senior leadership roles at SANIFIT, Orexigen Therapeutics, and Amgen.( His education includes an M.D. from the University of Nebraska Medical Center and an M.H.S. in medicine/nephrology from Duke University School of Medicine.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.